NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will participate in a fireside chat at the
upcoming Jefferies Next Generation IBD Therapeutics Virtual Summit
Date: Wednesday, September 23,
Time: 8 a.m. EDT
A live and archived webcast will be available at
https://wsw.com/webcast/jeff143/ptgx/1876505 and in the
Investors section of the Protagonist Therapeutics website at
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. The Company currently has three clinical-stage assets.
PTG-300 is an injectable hepcidin mimetic in development for the
treatment of polycythemia vera and other blood disorders. PTG-200
is an orally delivered, gut-restricted, interleukin-23 receptor
specific antagonist peptide in development for the treatment of
inflammatory bowel disease, with Crohn's disease as the initial
indication. The Company has a worldwide license and collaboration
agreement with Janssen Biotech, Inc., for the development of
PTG-200. PN-943 is an orally delivered, gut-restricted
alpha-4-beta-7 integrin specific antagonist peptide in development
for the treatment of inflammatory bowel disease, with ulcerative
colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original content to download
SOURCE Protagonist Therapeutics, Inc.